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Abstract
Traumatic brain injury (TBI) is a leading cause of death and disability in the
modern society. Although primary prevention is the only strategy that can
counteract the primary brain damage, numerous preclinical studies have been
accumulated in order to find therapeutic strategies against the secondary
damage. In this scenario erythropoietin (EPO) has been shown to be a
promising candidate as neuroprotective agent. A recent clinical trial, however,
has shown that EPO has not an overall effect on outcomes following TBI thus
renewing old concerns.  However, the results of a prespecified sensitivity
analysis indicate that the effect of EPO on mortality remains still unclear.
In the light of these observations, further investigations are needed to resolve
doubts on EPO effectiveness in order to provide a more solid base for tailoring
conclusive clinical trials.
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Traumatic brain injury (TBI) is one of the major causes of death and 
disability in our society1. TBI can provides heterogeneous effects 
since, in addition to the primary injury, it is associated with the 
so-called secondary brain injury where inflammation, excitotoxic-
ity, ischemia, edema participate in worsening the clinical scenario13. 
Several pre-clinical studies have been conducted in order to iden-
tify neuroprotective agents able to counteract the secondary tissue 
damage and improve clinical outcomes8. However, translation to 
the clinical trials has been discouraging and the treatment of TBI 
remains great challenge worldwide.
In both pre-clinical and clinical studies, erythropoietin (EPO) has 
been recognized for nearly two decades as a potent neuroprotec-
tive agent with a multifaceted, hematopoiesis-independent action 
profile4. The discovery that EPO has neuroprotective functions 
apart from regulating erythropoiesis3 was unexpected and prompted 
numerous studies showing a protecting role through antiapoptotic, 
antioxidative and anti-inflammatory, angiogenic and neurotrophic 
mechanisms7,9.
The recent conclusion of the EPO-TBI, double-blind randomized 
controlled trial10, has renewed old concerns. This clinical study was 
undertaken in 29 centers in seven countries. A total of 606 patients 
were randomly selected. EPO was given to 308 patients in a dose 
of 40,000 units subcutaneously, while 298 patients received a pla-
cebo, consisting of 0.9% sodium chloride,. Both EPO and placebo 
were administered once per week for a maximum of three doses. 
Randomization was stratified by severity of traumatic brain injury 
(moderate vs. severe) and participating site10. The primary outcome, 
consisting of improvement in the patients’ neurological status was 
measured at 6 months follow-up. It was summarized as a binary 
midpoint reduction of their extended Glasgow Outcome Scale 
(GOS-E) level, which was defined as a GOS-E of 1–4 (death, veg-
etative state, and severe disability) or a GOS-E of 5–8 (moderate 
disability and good recovery). In addition, mortality, proximal deep 
venous thrombosis and occurrence of general thrombotic events 
were assessed as secondary outcomes measures10.
The authors found that EPO did not reduce the number of patients 
with a GOS-E level of 4 or lower, and did not affect the incidence 
of deep venous thrombosis events.
Overall, the results of this international multicenter randomized 
placebo-controlled trial suggest that EPO may not be useful in TBI. 
This result is in contrast with a number of experimental studies 
suggesting that EPO might improve neurological outcomes follow-
ing TBI. However, the results of a prespecified sensitivity analysis 
adjusting for covariates indicate that the effect of EPO on mortality 
remains to be better investigated. Notably, although in this study 
EPO did not have an overall effect on survival10, when adjusted for 
illness severity according to the IMPACT-TBI predicted probability 
of a poor outcome, 6-months mortality was lower in patients given 
EPO than in those who received placebo.
Although the authors suggest caution in the interpretation of these 
mortality findings, we believe this question is worthy of note and 
remains to be addressed. The time window for EPO administration 
following TBI and its dose regimen are the main arguments. In this 
study a 24 hours time window and a dose of 40,000 units was chosen. 
It must be taken into account that earlier preclinical studies showed 
that recombinant human EPO treatment at a dose of 1000 IU/kg 
administered every 8 hours starting following TBI, is effective as 
neuroprotective agent5. The dose used in the study by Nichol and 
collaborators14 is the lowest dosage known to be effective in the 
experimental settings, and the time for the first administration, an 
average of 18.6 hours after TBI, would initiate a neuroprotective 
program in a late secondary damage. The small dose used, time 
and frequency of administration could contribute to the unfavora-
ble results from this clinical trial. Neuroprotective drugs should be 
administered as soon as possible and as long as the pathological 
cascades occur. EPO dose and therapeutic duration were clearly 
dictated by the concerns on the safety of recombinant human EPO. 
It is well known that all the information available regarding the 
safety of EPO comes from its non-neurologic use15. Using the infor-
mation accumulated on EPO safety in patients affected by chronic 
anemia and put into practice for the management of TBI can be dan-
gerous since the interaction between EPO and various physiologic 
variables, in addition to drugs commonly used in TBI patients, are 
unknown.
Additionally, besides its fame of a well-tolerated drug, recent 
reports of adverse effects associated with the chronic administra-
tion of recombinant EPO (i.e. hypertension, hypertensive encepha-
lopathy, seizures, and thrombotic/vascular events) have raised new 
concerns6. Although in experimental and clinical studies, including 
this randomized trial, no adverse effects during EPO treatment were 
observed, it is unknown what the effect in patients with a raised 
hemoglobin concentration would be.
Taken collectively, the findings of this recent clinical trial11, together 
with those from previous randomized studies2,12,14, suggest that EPO 
might decrease mortality in this patient group.
The overall disappointing results of the clinical trials reported over 
the time could be due to protocol and dosage problems, and one 
should also bear in mind that it is not always possible to translate 
animal research to the clinical scenario, which is more complex and 
less controlled.
More attention should be paid in conducting clinical trials in order 
to obtain sufficient information regarding therapeutic time window, 
dosage, duration of therapy and safety. The uncertain results so 
far obtained put EPO at risk of being discarded as thoroughly as 
it was initially welcomed as a miracle drug. Meanwhile, better 
information on the spectrum of biological actions of EPO and the 
underlying mechanisms would provide a more solid base for 
tailoring conclusive clinical trials.
In the light of these observations, further investigations are required 
to resolve such uncertainties especially when issues as optimal 
dosages, therapeutic time window, and duration of therapy deserve 
to be clarified.
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EPO, TBI and some more to say
In their opinion article, “Is erythropoietin a worthy candidate for traumatic brain injury or are we heading
Giovanni Grasso, Concetta Alafaci and Pietro Ghezzi address a very important topic.the wrong way?” 
Specifically, they summarize and comment on recent formally negative clinical trials on the use of
recombinant human erythropoietin (EPO) in traumatic brain injury (TBI). More globally, they lay their
fingers in the wound of numerous clinical trials on neuroprotection and neuroregeneration in brain
diseases that failed in translation from preclinical studies to the patient. The authors discuss briefly
properties and encouraging preclinical studies on EPO, and then raise the most critical issues of the
human EPO trials in TBI, mainly the late administration of the first dose, the short duration and low
frequency of treatment - all essentially dictated by not too well established safety concerns.
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frequency of treatment - all essentially dictated by not too well established safety concerns.
While we fully agree on most of these points, we do not think that the single dose was necessarily too low,
as also criticized by the authors. We feel that the dose was likely sufficient but that intravenous rather than
subcutaneous dosing should have been used to achieve higher EPO levels in the brain.
We would like to add a few comments that we feel – after 20 years of own experience in translational work
on the brain EPO system – are important to consider.
We had to painfully learn ourselves the downstream consequences of pharmaceutical companies and
overeager regulatories drawing fast conclusions out of too superficially or not at all analyzed data. This
triggered an avalanche of destruction regarding our large EPO stroke multicenter trial where severe
treatment violations of stroke patients in several centers (totally independent of the study medication)
explained the outcome rather than EPO . In fact, careful subpopulation analysis of all dead patients
revealed that several relevant baseline characteristics (i.e. data obtained  administration of anybefore
study medication) were significantly different between groups, always in disadvantage of the EPO group.
Most importantly, upon inclusion (before any study drug application), intent-to-treat non-rtPA receiving
EPO patients who died suffered from much severer strokes as compared to placebo patients (NIHSS day
1: 20.4±5.4 versus 13.3±4.9; p=0.003). This highly significant prediction of a worse outcome explains the
twofold higher very early death rate in the EPO group ( ).http://www.epo-study.de/index_eng.html
Unfortunately, the premature jumping to conclusions regarding the EPO stroke trial influenced also one of
the TBI trials discussed here: The authors write that “there was concern by the FDA that the initial regimen
of 3 daily doses of EPO would impose a greater risk of death. This concern resulted in a modified study
design after approximately one-third of the patients had been enrolled in the trial. We did not detect an
increased mortality rate with the EPO dose regimen, and the neurological outcome results were more
promising than with the subsequent regimen. However, because the original dose regimen was stopped
.early, the numbers of cases are too small to draw any conclusions”
Even though safety is undoubtedly an important issue, we have to reduce the incredible arrogance of
dismissing any trial that shows ‘just signals’ of benefit. How can we expect more in an initial translational
step? Being aware that there are no neuroprotective/neuroregenerative treatments out for conditions as
frequent and detrimental as stroke or TBI, it would be time to work hard on any positive signals rather than
‘throw the baby out with the bathwater’.
And clearly, both TBI trials  show such signals. Regarding stroke, not only the first EPO trial was
obviously promising , but also the retrospective analysis of patients from Hannover, the most efficiently
recruiting center of the second EPO stroke trial , made the beneficial effect of EPO in stroke again very
obvious.
Getting back to the opinion paper by Grasso and colleagues, longer treatment duration - over many
weeks - may ultimately disclose the benefit of EPO also for TBI much stronger. Clinical studies on EPO in
chronic brain diseases (schizophrenia, multiple sclerosis, major and bipolar depression) with extended
treatment using high dose EPO over many weeks showed consistently advantageous effects on
cognition, motor function, and even reduction of brain matter loss. All these findings were in absence of
any appreciable side effects . Of course, in all clinical studies, the quality of patient care including alert
follow-up of individual patients at all times is mandatory .
Work on EPO indications outside the hematopoietic system has been difficult ever since. Large studies
would be needed with adequate funding. Funding agencies do not provide enough money and direct
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would be needed with adequate funding. Funding agencies do not provide enough money and direct
requests for financing to industry. Industry has not been supportive due to expired EPO patents and many
EPO biosimilar producers popping up, increasing the risk of ‘off-label-use’. Protection of the extremely
lucrative anemia market includes avoiding the risk of additional side effects in new indications.  
EPO is a potent growth factor, not a miracle drug, and it is not a causal treatment or cure of brain diseases
but it may improve their outcome. Even though doping is an unpleasant chapter in itself, it may be seen in
the present context as one of the most convincing field studies ever regarding efficiency of EPO. Who
would invest huge amounts of money over decades and risk to be caught by controllers and convicted if
EPO were not extremely effective?
Despite all frustrations and disappointments: We have to keep trying to understand how EPO acts in the
brain and to ultimately exploit this knowledge for the benefit of our patients. Some novel and surprising
insight, lending further support to the use of EPO for neuroprotective and neuroregenerative treatment of
brain diseases, comes from recent studies showing that EPO increases the number of neurons and
oligodendrocytes in the hippocampus by driving pre-existing precursors to differentiate , or from work
reporting EPO effects on synaptic plasticity .
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